Health knowledge made personal
Join this community!
› Share page:
Search posts:

Aarkstore Enterprise Five Prime Therapeutics, Inc. – Product Pipeline Review – Q2 2011

Posted Jul 15 2011 9:37am


Company’s pharmaceuticals report, “Five Prime Therapeutics, Inc. - Product Pipeline Review - Q2 2011” provides data on the Five Prime Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.  

This report is built using data and information sourced from Company’s proprietary databases, Five Prime Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Five Prime Therapeutics, Inc. and industry-specific third party sources, put together by Company’s team.  


- Five Prime Therapeutics, Inc. - Brief Five Prime Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Five Prime Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Five Prime Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.  
- Recent updates of the Five Prime Therapeutics, Inc.’s pipeline in the last quarter.  
- Key discontinued and dormant projects.  
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Five Prime Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.  
- Assess the growth potential of Five Prime Therapeutics, Inc. in its therapy areas of focus.  
- Identify new drug targets and therapeutic classes in the Five Prime Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.  
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.  
- Exploit collaboration and partnership opportunities with Five Prime Therapeutics, Inc..  
- Avoid Intellectual Property Rights related issues.  
- Explore the dormant and discontinued projects of Five Prime Therapeutics, Inc. and identify potential opportunities in those areas.

For more information please visit link:

Related Reports

Post a comment
Write a comment:

Related Searches